ライフサイエンスコーパス: interleukin-1 receptor

1 ream of multiple Toll-like receptors and the interleukin-1 receptor.

2 ner dependent on signaling downstream of the interleukin-1 receptor.

3 s the key signaling adapter of Toll-like and interleukin-1 receptors.

4 or the upstream mediator of its expression, interleukin 1 receptor 1.

5 In this study, we identified interleukin-1 receptor 1 (IL1R1) as a mediator of celast

6 In the amygdala significant up-regulation of interleukin-1 receptor 1 (IL1r1), interleukin-4 receptor

7 The 28-kDa form of IL-1beta cannot activate interleukin-1 receptor-1 (IL1R1) to signal inflammatory

8 terleukin-6) and alloimmune activation (CD3, interleukin-1 receptor 2, programmed cell death-1, and s

9 rferon-gamma, interleukin-6) and alloimmune (interleukin-1 receptor 2, programmed cell death-1, and s

10 013) describe a molecular system implicating interleukin-1 receptor-2 (IL-1R2) as a principal cytosol

11 to caspase proteolytic activity that cleaves interleukin-1 receptor-2, allowing IL-1alpha dissociatio

12 n assays show that IL-1alpha associates with interleukin-1 receptor-2, and this association is decrea

13 in 1 pathway, through either ablation of the interleukin 1 receptor 8 (IL-1R8, also known as SIGIRR o

14 Interleukin-1 receptor 8 (IL-1R8, also known as single i

15 elated (SIGIRR), which is also known as Toll/interleukin-1 receptor 8 (TIR-8), is a member of the TIR

16 rinsic to B cells and was independent of the interleukin-1 receptor, a cytokine receptor that also si

17 The interleukin 1 receptor accessory protein (IL1RAP; IL1R3)

18 Interleukin-1 receptor accessory protein (IL1RAP; IL1R3)

19 Mutations and deletions of the interleukin-1 receptor accessory protein like 1 (IL1RAPL

20 the X-linked intellectual disability protein interleukin-1 receptor accessory protein like 1 (IL1RAPL

21 E) epsilon4 status was identified in IL1RAP (interleukin-1 receptor accessory protein; rs12053868-G;

22 e signal transduction pathways after TLR and interleukin-1 receptor activation.

23 ndings broaden our understanding of how Toll/interleukin-1 receptor adaptor proteins may participate

24 TLR2 and TLR4 signal via the Toll/interleukin-1 receptor adaptors MyD88 and MAL, leading t

25 t of T2D, including the inflammation markers interleukin-1 receptor agonist (IL-1RA) and high-sensiti

26 IRAK-4 and MyD88 deficiencies impair interleukin 1 receptor and Toll-like receptor (TLR) sign

27 h rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist (IL-1RA) (P = .005 and

28 Serum interleukin 1 receptor antagonist (IL-1RA) levels were e

29 centrations of interleukin 1beta (IL-1beta), interleukin 1 receptor antagonist (IL-1Ra), and granuloc

30 lymorphisms of interleukin 1 beta (IL1B) and interleukin 1 receptor antagonist (IL1RA) genes for asso

31 rogation of the MSC transcriptome identified interleukin 1 receptor antagonist (IL1RN) as a potential

32 nd, even more importantly, anti-inflammatory interleukin 1 receptor antagonist (IL1Rn).

33 d P = .00005 for IMI, by the log-rank test), interleukin 1 receptor antagonist (IL1RN; rs419598; P =

34 Finally, inclusion of interleukin 1 receptor antagonist (Kineret(R)) in the ad

35 nduced protein [IP-10]) and proinflammatory (interleukin 1 receptor antagonist [IL-1RA], IL-6) cytoki

36 sis revealed an inverse relationship between interleukin 1 receptor antagonist and colony-stimulating

37 itric oxide synthase, interleukin-1beta, and interleukin 1 receptor antagonist but not transforming g

38 roglial numbers, increased interleukin 6 and interleukin 1 receptor antagonist messenger RNA, alterat

39 Finally, early acute levels of interleukin 1 receptor antagonist were associated with t

40 lts showed a significant increase in IL-1RA (interleukin 1 receptor antagonist) mRNA expression and a

41 ectrin breakdown product 150, interleukin 6, interleukin 1 receptor antagonist, and c-reactive protei

42 tory factor/glycosylation-inhibiting factor, interleukin 1 receptor antagonist, and serine protease i

43 in 6, granulocyte colony-stimulating factor, interleukin 1 receptor antagonist, and vascular endothel

44 Potential immune markers, including interleukin 1 receptor antagonist, interferon gamma-indu

45 Tear concentrations increased for interleukin-1 receptor antagonist (16 557.1 +/- 4047.8 v

46 the impact of an exogenous recombinant human interleukin-1 receptor antagonist (anakinra) in experime

47 multifocal osteomyelitis, deficiency of the interleukin-1 receptor antagonist (DIRA), Majeed syndrom

48 10 kDa (IP-10) (53-fold) and an increase in interleukin-1 receptor antagonist (IL-1ra) (5-fold) were

49 lute partial correlation coefficients >0.40: Interleukin-1 receptor antagonist (IL-1Ra) and IL-8.

50 f the folded and unfolded ensembles of human interleukin-1 receptor antagonist (IL-1ra) are strongly

51 ty of the method was demonstrated with human interleukin-1 receptor antagonist (IL-1ra) as a protein

52 Interleukin-1 receptor antagonist (IL-1Ra) deficiency is

53 L-1beta and its regulation by the endogenous interleukin-1 receptor antagonist (IL-1ra) in glutamate

54 We therefore examined the influence of interleukin-1 receptor antagonist (IL-1Ra) on MCL healin

55 e investigated whether the anti-inflammatory interleukin-1 receptor antagonist (IL-1Ra) prevents muri

56 itors enhance the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1Ra) secretion in

57 production of the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL-1RA) that could be

58 and structural behavior of human recombinant interleukin-1 receptor antagonist (IL-1ra) was revealed

59 Notably, the hepatic expression of interleukin-1 receptor antagonist (IL-1ra) was suppresse

60 Levels of interleukin-1 receptor antagonist (IL-1Ra) were determin

61 necrosis factor (TNF) receptor-2 (TNFR2) and interleukin-1 receptor antagonist (IL-1ra) were fused to

62 Structural properties and folding of interleukin-1 receptor antagonist (IL-1ra), a therapeuti

63 The endogenous interleukin-1 receptor antagonist (IL-1Ra), an inflammat

64 culating levels of C-reactive protein (CRP), interleukin-1 receptor antagonist (IL-1Ra), and soluble

65 6), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 receptor antagonist (IL-1RA), and transfor

66 so occurred, with GVHD-specific secretion of interleukin-1 receptor antagonist (IL-1Ra), IL-18, and C

67 single IFN target gene, Il1rn, which encodes interleukin-1 receptor antagonist (IL-1Ra), is sufficien

68 otype of the tumour through the secretion of interleukin-1 receptor antagonist (IL-1RA).

69 experiments using recombinant type I IFN and interleukin-1 receptor antagonist (IL-1ra).

70 at a single intracisternal administration of interleukin-1 receptor antagonist (IL-1RA; 112 mug) at t

71 sma levels of neopterin (P<;0.0001), soluble interleukin-1 receptor antagonist (P<;0.0001), IL-8 (P=0

72 nd methionine oxidation in recombinant human interleukin-1 receptor antagonist (rhIL-1ra) was investi

73 interleukin-10 (IL-10), and increased plasma interleukin-1 receptor antagonist (sIL-1ra) and soluble

74 6], tumor necrosis factor-alpha [TNF-alpha], interleukin-1 receptor antagonist [IL-1RA], and transfor

75 D and confirmed six proteins (leptin, renin, interleukin-1 receptor antagonist [IL-1ra], hepatocyte g

76 ate immune system and chemotactic signaling (interleukin-1 receptor antagonist [IL-1Ra], IL-6, IL-8,

77 that can be blocked by administration of an interleukin-1 receptor antagonist and a specific p38 MAP

78 The biologic agents interleukin-1 receptor antagonist and antitumor necrosis

79 3), and antiinflammatory markers (increased interleukin-1 receptor antagonist and lower monocyte and

80 py efficacy stemmed from the upregulation of interleukin-1 receptor antagonist and suppression of MDS

81 Recent studies have also focused on the interleukin-1 receptor antagonist and the melanocortin-1

82 rosis factor-alpha and interleukin-6 and the interleukin-1 receptor antagonist compared with control

83 Experimental interleukin-1 receptor antagonist gene overexpression ha

84 ombinant activated protein C, talactoferrin, interleukin-1 receptor antagonist in sepsis, and muscle

85 ntagonist gene overexpression has shown that interleukin-1 receptor antagonist is cardioprotective du

86 ral infiltrates are associated with elevated interleukin-1 receptor antagonist or interleukin-8 and 2

87 l activation by minocycline or by transgenic interleukin-1 receptor antagonist overexpression rescued

88 in plasma interleukin-8, interleukin-10, and interleukin-1 receptor antagonist posttransfusion compar

89 Systemic delivery of interleukin-1 receptor antagonist protected SN DA neuron

90 The use of an interleukin-1 receptor antagonist to control wound pain

91 akinra is a recombinant version of the human interleukin-1 receptor antagonist used to treat autoinfl

92 ling for age, gender, and primary diagnosis, interleukin-1 receptor antagonist was higher on study da

93 nd 2, C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist were measured in 233 i

94 or necrosis factor-alpha, interleukin-6, and interleukin-1 receptor antagonist), their mRNA expressio

95 occurring antiinflammatory cytokine IL-1Ra (interleukin-1 receptor antagonist).

96 associated with augmented concentrations of interleukin-1 receptor antagonist, a key anti-inflammato

97 alpha2beta1 integrin polyclonal antibodies, interleukin-1 receptor antagonist, and the chemical inhi

98 interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved beta-cell fu

99 The temporal patterns of interleukin-1 receptor antagonist, intercellular adhesio

100 We investigated the effects of anakinra, an interleukin-1 receptor antagonist, on coronary and left

101 Component 1 (interleukin-1 receptor antagonist, QA, and kynurenine) w

102 ed growth factor receptors, and anakinra, an interleukin-1 receptor antagonist, respectively, increas

103 ly attenuated by treatment with anakinra, an interleukin-1 receptor antagonist.

104 effects are prevented by pre-application of interleukin-1 receptor antagonist.

105 atinase-associated lipocalin, protein C, and interleukin-1 receptor antagonist.

106 eating glutathione peroxidase 1 mice with an interleukin-1 receptor antagonist.

107 We hypothesized that administration of IL-1 (interleukin-1) receptor antagonist (anakinra) could inhi

108 ily members, including the gene encoding the interleukin-1-receptor antagonist (IL1RN).

109 The absence of interleukin-1-receptor antagonist allows unopposed actio

110 to empirical treatment with the recombinant interleukin-1-receptor antagonist anakinra in the first

111 We propose the term deficiency of the interleukin-1-receptor antagonist, or DIRA, to denote th

112 sed by mutations of IL1RN, which encodes the interleukin-1-receptor antagonist, with prominent involv

113 regulation of 2 inhibitors of TLR signaling: Interleukin 1 Receptor Associated Kinase (IRAK) M, and S

114 differentiation primary response 88 (MYD88)/interleukin-1 receptor associated kinase (IRAK) pathway,

115 88 L265P mutant results in the activation of interleukin-1 receptor associated kinase (IRAK).

116 gh tyrosine nitration-mediated impairment of interleukin-1 receptor associated kinase (IRAK)4, a sign

117 a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 (IRAK4) using

118 s undertaken to test the candidacy of IRAK1 (interleukin-1 receptor associated kinase-1) as an X chro

119 canonical downstream signaling intermediates interleukin 1 receptor-associated kinase (IRAK) and Ikap

120 n primary murine macrophages, dependent upon interleukin 1 receptor-associated kinase (IRAK-1).

121 mammals and overlaps with the 5' UTR of the interleukin 1 receptor-associated kinase (IRAK1) gene.

122 of EGFR and the NF-kappaB regulatory kinase interleukin 1 receptor-associated kinase 1 (IRAK-1).

123 This included a Phe196Ser change in the interleukin 1 receptor-associated kinase 1 (IRAK1).

124 Interleukin 1 receptor-associated kinase 1(IRAK1), a key

125 Interleukin-1 receptor-associated kinase (IRAK) -1 plays

126 e residues in the known TLR pathway kinases, Interleukin-1 receptor-associated kinase (IRAK) 2 and IR

127 pathway involving the MyD88 adapter and the interleukin-1 receptor-associated kinase (IRAK) complex.

128 IRAK2, a member of the interleukin-1 receptor-associated kinase (IRAK) family,

129 nes encoding non-RD kinases belonging to the interleukin-1 receptor-associated kinase (IRAK) family.

130 pretreatment in vivo inhibited expression of interleukin-1 receptor-associated kinase (IRAK)-1 while

131 Here, we show that the interleukin-1 receptor-associated kinase (IRAK)/Pelle-li

132 s study, we examined the contribution of the interleukin-1 receptor-associated kinase 1 (IRAK-1) to L

133 id differentiation primary response (MyD88), interleukin-1 receptor-associated kinase 1 (IRAK-1), and

134 ion with NF-kappaB-inducing kinase (NIK) and interleukin-1 receptor-associated kinase 1 (IRAK-1), deg

135 Here we report that interleukin-1 receptor-associated kinase 1 (IRAK1) is ov

136 Inhibition of BTK or interleukin-1 receptor-associated kinase 1 and 4 (IRAK-1

137 use of TMP with Bruton's tyrosine kinase or interleukin-1 receptor-associated kinase 1 and 4 inhibit

138 rvival pathway, leading to downregulation of interleukin-1 receptor-associated kinase 1.

139 ed NFkappaB activation, via interaction with interleukin-1 receptor-associated kinase 2 (IRAK2).

140 B cells isolated from patients deficient for interleukin-1 receptor-associated kinase 4 (IRAK-4), mye

141 onse was reversed in the patient, but not in interleukin-1 receptor-associated kinase 4 (IRAK-4)-defi

142 Interleukin-1 receptor-associated kinase 4 (IRAK4) is a

143 Interleukin-1 receptor-associated kinase 4 (IRAK4) plays

144 Interleukin-1 receptor-associated kinase 4 (IRAK4) was t

145 ying very rare loss-of-function mutations in interleukin-1 receptor-associated kinase 4 (IRAK4), a cr

146 Interleukin-1 receptor-associated kinase 4 (IRAK4), a ma

147 diminished degradation and interaction with interleukin-1 receptor-associated kinase 4 (IRAK4).

148 he Toll-like receptor (TLR) pathway, such as interleukin-1 receptor-associated kinase 4 deficiency, h

149 R4-mediated signaling pathway (reduced MyD88-interleukin-1 receptor-associated kinase [IRAK] interact

150 Abs induced activation of TLR4 and triggered interleukin-1 receptor-associated kinase phosphorylation

151 main containing adaptor protein)-MyD88-IRAK (interleukin-1 receptor-associated kinase)1/4-TRAF6 (TNF

152 Interleukin-1 receptor-associated kinase-1 (IRAK-1) and

153 o-1 actions were likely to be independent of interleukin-1 receptor-associated kinase-1 (IRAK-1) regu

154 miRNA-146a down-regulates expression of the interleukin-1 receptor-associated kinase-1 (IRAK-1), an

155 h diminished IL-1beta-induced degradation of interleukin-1 receptor-associated kinase-1 (IRAK-1).

156 gulating Lys-63-linked polyubiquitination of interleukin-1 receptor-associated kinase-1 (IRAK1) by th

157 pression, myeloid differentiation factor 88, interleukin-1 receptor-associated kinase-1, and nuclear

158 Interleukin-1 receptor-associated kinase-4 (IRAK-4) is a

159 Within innate immune signaling pathways, interleukin-1 receptor-associated kinases (IRAKs) fulfil

160 its DD and TIR domain and interacts with the interleukin-1 receptor-associated kinases (IRAKs) to for

161 A possible involvement of the gene IL1RAP (interleukin-1 receptor-associated protein) in the pathog

162 In this subgroup analysis, interleukin-1 receptor blockade was associated with sign

163 ctivation syndrome features may benefit from interleukin-1 receptor blockade.

164 entricular assist device, treatment with the interleukin-1 receptor blocking agent anakinra 100 mg/d

165 nt with fulminant viral myocarditis with the interleukin-1 receptor blocking agent anakinra.

166 arized macrophages that highly expresses the interleukin-1 receptor, CD206 and interleukin-4 receptor

167 ma infection than wild-type, Dectin-1-/-, or interleukin 1 receptor-deficient (IL-1R-/-) mice.

168 Interleukin-1 receptor-deficient (IL-1R(-/-)) mice are h

169 le nucleotide polymorphism A471T in the Toll-interleukin 1 receptor domain (TIR) of the IL-1Rrp2 that

170 ctivate downstream signaling via TIRAP (Toll-interleukin 1 receptor domain containing adaptor protein

171 Toll-interleukin 1 receptor domain NLRs (TNLs) converge on th

172 ne spanning region and an intracellular Toll/Interleukin 1 receptor domain which invokes signal trans

173 d differentiation factor 88 (MyD88) and toll/interleukin 1 receptor domain-containing adapter inducin

174 d differentiation factor 88 (MyD88) and Toll-interleukin 1 receptor domain-containing adapter inducin

175 8-independent TLR signals by inhibiting Toll/interleukin 1 receptor domain-containing adaptor inducin

176 rimary response protein 88 (MyD88), and Toll interleukin 1 receptor domain-containing adaptor protein

177 with mice lacking signaling through the Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein

178 ndicating that the Toll-6 receptor, the Toll/interleukin-1 receptor domain adaptor dSARM, and FoxO fu

179 Pharmacologic and genetic disruption of Toll/interleukin-1 receptor domain-containing adapter inducin

180 The TLR adaptor Toll/interleukin-1 receptor domain-containing adapter-inducin

181 d differentiating factor 88 (MyD88) and Toll/interleukin-1 receptor domain-containing adapter-inducin

182 cell line Mono Mac 6, induction of the Toll-interleukin-1 receptor domain-containing adaptor-inducin

183 duced autophagy was regulated through a Toll-interleukin-1 receptor domain-containing adaptor-inducin

184 production of ETs by S cells requires a Toll/Interleukin-1 receptor domain-containing protein TirA an

185 Toll/interleukin-1-receptor domain containing adaptor protein

186 e deficient in the TLR adaptor proteins Toll/interleukin-1 receptor-domain-containing adaptor protein

187 protein containing predicted lectin and Toll/Interleukin-1 receptor domains.

188 r the SAM (sterile alpha motif) or TIR (Toll-interleukin-1 receptor) domains abolishes the ability of

189 the patient-specific characteristics of the interleukin-1 receptor family member ST2 in patients wit

190 s to examine the value of measurement of the interleukin-1 receptor family member ST2 in patients wit

191 Four biomarkers, soluble form of ST2 (an interleukin-1 receptor family member), galectin-3, matri

192 ST2 is a member of the interleukin-1 receptor family with a soluble form that i

193 The interleukin-1 receptor I (IL-1RI) is critical for host r

194 chemoattractant protein-1, resistin, soluble interleukin-1 receptor I, soluble interleukin-2 receptor

195 The interleukin 1 receptor (IL-1R) and the Toll-like recepto

196 activation is mediated through TRAF6 in the interleukin 1 receptor (IL-1R) and toll-like receptor (T

197 h their role in Toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) mediated signaling pathwa

198 LLIP) regulates Toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling against mycobac

199 ive influenza A virus, signaling through the interleukin 1 receptor (IL-1R) was required for producti

200 DA-5), as well as cytokine receptors such as interleukin 1 receptor (IL-1R), have been implicated in

201 ated innate signaling pathway, as well as in interleukin-1 receptor (IL-1R) and IL-18R signaling.

202 Stimulation through the interleukin-1 receptor (IL-1R) and some Toll-like recept

203 d was first characterized as an inhibitor of interleukin-1 receptor (IL-1R) and Toll-like receptor (T

204 on of IRAK1, a kinase thus far implicated in interleukin-1 receptor (IL-1R) and Toll-like receptor (T

205 nown that TLR3 uses the adaptor protein Toll/interleukin-1 receptor (IL-1R) domain-containing adaptor

206 members of the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) families transduce signal

207 ta (IkappaBzeta), a Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) inducible transcription f

208 We found that Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling dynamics relied

209 ), a negative regulator of the Toll-like and interleukin-1 receptor (IL-1R) signaling pathways, contr

210 Here we show that interleukin-1 receptor (IL-1R) signaling protects mice f

211 e expression of the Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) superfamily, IL-1beta pro

212 Surprisingly, the interleukin-1 receptor (IL-1R) was required for an AEC c

213 ting microglia expressed high amounts of the interleukin-1 receptor (IL-1R), and treatment with an IL

214 a signaling adaptor shared by most TLRs and interleukin-1 receptor (IL-1R), in an in vitro model of

215 c expression of toll-like receptor 4 (TLR4), interleukin-1 receptor (IL-1R), or interferon-gamma rece

216 Interleukin-1 receptor (IL-1R)-associated kinase (IRAK)

217 We identified interleukin-1 receptor (IL-1R)-associated kinase 1 (IRAK

218 inhibitors to assess the regulatory roles of interleukin-1 receptor (IL-1R)-associated kinase 4 (IRAK

219 fied nearly two decades ago as a mediator of interleukin-1 receptor (IL-1R)-mediated activation of NF

220 ponses are controlled through members of the interleukin-1 receptor (IL-1R)/Toll-like receptor superf

221 The type 1 interleukin-1 receptor (IL-1R1) mediates diverse functio

222 Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs) have TIR intracellular

223 in that links toll-like receptors (TLRs) and Interleukin-1 receptors (IL-1Rs) with downstream signali

224 evoked by the Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs).

225 D88(-/-), MyD88/TLR adaptor molecule 1(-/-), interleukin-1 receptor [IL-1R1](-/-), and interleukin (I

226 00 [UL = unique long]) and host-genes (e.g., interleukin-1 receptor, IRF1).

227 d deficiencies in the inflammatory response, interleukin-1 receptor knockout (IL-1R(-/-)) and caspase

228 -/-)), caspase-1 knockout (Casp-1(-/-)), and interleukin-1 receptor knockout (IL-1R(-/-)) mice treate

229 We have reported that signaling in interleukin-1-receptor-knockout (IL-1R1(-/-)) mice leads

230 ied the expression of IL36 and its receptor, interleukin 1 receptor like 2 (IL1RL2 or IL36R) in the d

231 ivates many immune cell types expressing the interleukin 1 receptor-like 1 (IL1RL1) receptor ST2, inc

232 Interleukin 1 receptor-like 1 (IL1RL1), also known as su

233 hil C-C chemokine receptor type 3 (CCR3) and interleukin 1 receptor-like 1 (ST2) in vivo.

234 dipocyte differentiation, whereas Got2, Cpq, interleukin-1 receptor-like 1/ST2-IL-33, Sparc, and Lgal

235 mune receptors containing an N-terminal Toll-interleukin-1 receptor-like domain (TNLs) in Arabidopsis

236 Interleukin-1-receptor-like-1 (IL1RL1 or ST2) is a well-

237 because deletion of Nlrp3, caspase-1 and the interleukin-1 receptor markedly protects against rheumat

238 Sterile alpha and Toll/interleukin-1 receptor motif-containing protein 1 (SARM1

239 uide cleavage of transcripts of the Toll and Interleukin-1 receptor-NB-LRR immune receptor N from tob

240 r-triggered immunity conditioned by the Toll Interleukin-1 Receptor-nucleotide binding (NB)-Leu-rich

241 gered immunity specifically mediated by Toll-interleukin-1 receptor-nucleotide binding-leucine-rich r

242 RCT1 is a member of the Toll-interleukin-1 receptor/nucleotide-binding site/leucine-r

243 all genes predicted to contain either a Toll/interleukin-1 receptor or nucleotide-binding site domain

244 Single-immunoglobulin interleukin-1 receptor-related (SIGIRR), which is also k

245 in their N-terminal domains: these are Toll/interleukin-1 receptor resistance (TIR) domain-containin

246 n primary response 88 adaptors, but not toll/interleukin-1 receptor/resistance [TIR] domain-containin

247 Single immunoglobulin and toll-interleukin 1 receptor (SIGIRR), a negative regulator of

248 In Toll-like receptor and interleukin-1 receptor signaling pathways, the kinase IR

249 mon adaptor for toll-like receptor (TLR) and Interleukin-1 receptor signaling, are critical for radio

250 -1 activity in bone marrow-derived cells and interleukin-1 receptor signaling.

251 rotein that mediates Toll-like receptors and interleukin-1 receptor signaling.

252 ucially relies on the Nlrp3 inflammasome and interleukin-1 receptor signalling.

253 ignaling by the toll-like receptor (TLR) and interleukin-1 receptor superfamily requires the adapter

254 ch signal through adaptors containing a Toll-interleukin 1 receptor (TIR) domain, such as MyD88 and T

255 TRIF is a Toll-interleukin 1 receptor (TIR) domain-containing adapter p

256 n primary response gene 88 (MyD88)- and Toll-interleukin 1 receptor (TIR) domain-containing adaptor i

257 Here, we describe a Toll/interleukin 1 receptor (TIR) domain-containing protein (

258 SENSITIVE 3 (CHS3) encodes an atypical Toll/Interleukin 1 Receptor (TIR)-type NLR protein with an ad

259 fied roles in IFN-I stimulation for the Toll-interleukin-1 receptor (TIR) adaptor Myd88 adaptor-like

260 plementation, and found that C15 in the Toll/interleukin-1 receptor (TIR) domain and L816 in the LRR

261 ve to Nicotiana benthamiana with a Toll-like interleukin-1 receptor (TIR) domain bound to the Xanthom

262 neurodegenerative process(5-8), and its Toll/interleukin-1 receptor (TIR) domain exerts its pro-neuro

263 Herein, by using the toll/interleukin-1 receptor (TIR) domain homologous C-termina

264 The Toll/interleukin-1 receptor (TIR) domain plays a crucial role

265 A Toll/interleukin-1 receptor (TIR) domain protein, TirA, was a

266 rly Leu265Pro (L265P), within the MyD88 Toll/interleukin-1 receptor (TIR) domain sustain lymphoma cel

267 e-rich repeat (NLR) protein with a Toll-like interleukin-1 receptor (TIR) domain, which mediates XopQ

268 Toll/interleukin-1 receptor (TIR) domain-containing adapter p

269 lipopolysaccharide, this is a delayed, Toll/interleukin-1 receptor (TIR) domain-containing adapter-i

270 ckouts including TLR2, TLR4, MyD88, and Toll-interleukin-1 receptor (TIR) domain-containing adaptor p

271 esponses by targeted degradation of the Toll/interleukin-1 receptor (TIR) domain-containing adaptor p

272 Toll-interleukin-1 receptor (TIR) domain-containing adaptor-i

273 Toll/interleukin-1 receptor (TIR) domain-containing adaptors

274 L6 is a Toll/interleukin-1 receptor (TIR) domain-containing NLR from

275 ults in dimerization of their cytosolic Toll/interleukin-1 receptor (TIR) domains and recruitment of

276 oth processes depend on closely related Toll/interleukin-1 receptor (TIR) domains in these proteins,

277 We demonstrate that plant Toll/interleukin-1 receptor (TIR) domains of NLRs are enzymes

278 Toll-like receptors (TLRs), cytoplasmic Toll/interleukin-1 receptor (TIR) domains of the receptors un

279 The heterotypic interaction between the Toll/interleukin-1 receptor (TIR) domains of TLRs and adaptor

280 aling adapter protein interactions with Toll/Interleukin-1 Receptor (TIR) domains present in sensory

281 signaling by dimerizing the cytoplasmic Toll interleukin-1 receptor (TIR) domains.

282 Analysis of Toll/interleukin-1 receptor (TIR) sequences indicated that th

283 illo motif (SARM) is a highly conserved Toll/interleukin-1 receptor (TIR)-containing adaptor protein

284 structures of MAL revealed a nontypical Toll/interleukin-1 receptor (TIR)-domain fold stabilized by t

285 equires the P loops of each protein and Toll/interleukin-1 receptor (TIR)-domain-mediated heteromeric

286 in Brescia (BICv) identified a putative Toll/interleukin-1 receptor (TIR)-like domain.

287 The majority of these belong to the Toll/Interleukin-1 receptor (TIR)-NBS-LRR (TNL) class.

288 lays an essential role in Toll-like receptor/interleukin-1 receptor (TLR/IL-1R) -associated NF-kappaB

289 can activate signaling by the Toll-like and interleukin-1 receptors (TLR and IL-1R) to mediate patho

290 signalling (tumour necrosis factor receptor/interleukin-1 receptor, TNFR/IL-1R in mammals) is indisp

291 ch are adaptor molecules that couple TNF and interleukin-1 receptor/Toll-like receptor family members

292 he negative regulation of Toll-like receptor/interleukin-1 receptor-triggered inflammatory cascades a

293 terleukin-1beta interacts with its receptor (interleukin 1 receptor type 1) on hematopoietic stem and

294 was developed to analyze recombinant soluble Interleukin 1 receptor type II (sIL-1R type II) drug sub

295 d the role of toll-like receptors (TLRs) and interleukin-1 receptor type 1 (IL-1R1) in S. marcescens-

296 nization, we show that mice deficient in the interleukin-1 receptor type 1 (Il1r1(-/-)) have reduced

297 y protein (IL1RAP; IL1R3) is a coreceptor of interleukin-1 receptor type 1 and has been found upregul

298 Interleukin-1 receptor type 2 (IL1R2) acts as a decoy re

299 Interleukin-1 receptor type I knockout mice, which displ

300 IC associated genes included the innate interleukin 1 receptor, type 1 and the antimicrobial pep